Brief Discussion on the Enlightenment of FDA’s Comparability Protocol to the Post-Approval Change Management of New Drugs in China

Abstract

Objective To discuss the flexible supervision and communication mode in the post-approval change (PAC) of drugs, to explore how to ensure the quality and availability of drugs during the changes, and to provide some suggestions and reference for promoting the timely marketing of drugs. Methods Based on the comparability protocol guidelines issued by the US FDA in October 2022, the regulatory status quo of PAC between China and the US was compared to explore the feasibility of implementing comparability protocols in China. Results and Conclusion According to the specific situation of post-approval of drug change supervision, some suggestions were put forward to optimize the PAC management procedure, such as establishing the communication pathways between holders and health authorities, publishing relevant guidance and strengthening training, so as to provide reference for the implementation of comparability protocols in China.

Keywords

post-approval change / quality risk management / risk assessment / comparability protocol / pharmaceutical quality system

References

[1] Center for Drug Evaluation, NMPA. Technical Guidance for CMC Changes of Innovative Drugs (Chemical Drugs) During Post Approval (Interim). [EB/OL]. (2021-02-10)[2023-01-17]. https://www.cde.org.cn/main/news/viewInfoCommon/4ec3dca752a82347bdf24ad3d3e85113.

[2] The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Pharmaceutical Quality System Q10 [EB/OL]. (2008-06-04)[2023-01-17]. https://database.ich.org/sites/default/files/Q10%20Guideline.pdf.

[3] ICH. Quality Risk Management Q9 (R1) [EB/OL]. (2023-01-18)[2023-02-01]. https://database.ich.org/sites/default/files/Q9%20Guideline.pdf.

[4] Ding Xiaohang, Fu Gongyi. Application of quality risk management in GMP implementation in pharmaceutical manufacturing enterprises[J]. Asian Journal of Clinical Medicine, 2020, 3 (4): 52-54.

[5] Ramnarine E, Vinther A, Bruhin K, et al. Effective management of pos t-approval changes in the pharmaceutical quality system (PQS) - through enhanced science and risk-based approaches industry one-voice-of-quality (1VQ) solutions[J]. Journal of Pharmaceutical Science and Technology, 2020, 74 (4): 456-470.

[6] Li Xiaoyu, Chai Qianwen, Tian Delong, et al. Research on manufacture changes of approved drugs in European and United States[J]. Chinese Journal of Pharmacovigilance, 2016, 13 (8): 476-481.

[7] US Federal. 21 CFR 314.70 Supplements and other changes to an approved NDA[EB/OL]. (2004-03-30)[2023-02-07]. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314/subpart-B/section-314.70.

[8] Office of the Federal Register. US Federal Register[EB/OL]. (2022-10-14)[2023-02-07]. https://www.govinfo.gov/content/pkg/FR-2022-10-14/pdf/2022-22334.pdf.

[9] FDA. Comparability Protocols for Post-Approval Changes to the Chemistry, Manufacturing, and Controls Information in an NDA, ANDA, or BLA[EB/OL]. (2022-10-14)[2023-02-10]. https://www.fda.gov/media/162263/download.

[10] Michaels JN, Bonsignore H, Hudson-Curtis BL, et al. Attribute-based design space: Material-science-based quality-by-design for operational flexibility and process portability[J]. Journal of Pharmaceutical Innovation, 2011, 6: 193-201.

[11] Garcia T, Cook G, Nosal R. PQLI key topics - criticality, design space, and control strategy[J]. Journal of Pharmaceutical Innovation, 2008, 3: 60-68.

[12] ICH. Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Q12 [EB/OL]. (2019-11-20)[2023-02-10]. https://database.ich.org/sites/default/files/Q12_Guideline_Step4_2019_1119.pdf.

[13] Li Cheng, Chen Guiliang. Regulatory thinking of post approval changes in China[J]. Chinese Journal of New Drugs, 2022, 31 (2): 155-159.

[14] CDE. Provisions for Drug Registration[EB/OL]. (2020-03-30)[2023-02-11]. https://www.cde.org.cn/main/policy/view/2f5d01af26ead0e3b149d99ad8022d8d.

[15] National Medical Products Administration (NMPA). Provisions for Post-Approval Changes of Drugs (Interim)[EB/OL]. (2021-01-13)[2023-02-11]. https://www.nmpa.gov.cn/xxgk/fgwj/xzhgfxwj/20210113142301136.html.

[16] Shanghai Medial Products Administration. Notices on the Communication of Post-approval Change Reporting Categories of Drugs[EB/OL]. (2021-01-29)[2023-02-11]. https://yjj.sh.gov.cn/zx-yp/20210129/f0a0c7ba41ea4e608f26009f9b37d7a7.html.

[17] Jiangsu Medical Products Administration. Notices on the Communication of Post-Approval Change Reporting Categories of Drugs[EB/OL]. (2021-03-03)[2023-02-11]. http://da.jiangsu.gov.cn/art/2021/3/3/art_65298_9686281.html.